Global growth markets investor The Abraaj Group has announced its full exit from Tunisia-based pharmaceutical company Opalia Pharma. The Abraaj Group, which originally invested in Opalia in 2009, sold its entire stake to Italy-listed Recordati, an international pharmaceutical company. In addition to The Abraaj Group’s stake, Recordati has agreed to acquire a total of 90 percent of Opalia Pharma. Financial details of the transaction were not disclosed.